Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist

Thrombosis Research

Volumn 99, Issue 6, 2000, Pages 603-612

  Buchanan, Michael R ^a   Brister, Stephanie J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Dermatan sulphate; Heparin; Intimatan; Surface bound thrombin

Indexed keywords

ANTITHROMBIN; DERMATAN SULFATE; HEPARIN; HEPARIN COFACTOR 2 AGONIST; HEPARIN COFACTOR II; INTIMATAN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOGENESIS;

ANIMALS; ANTICOAGULANTS; CAROTID ARTERY INJURIES; DERMATAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; HEPARIN; HEPARIN COFACTOR II; MALE; PARTIAL THROMBOPLASTIN TIME; RABBITS; SODIUM CHLORIDE; THROMBIN;

EID: 0034666733     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00276-0     Document Type: Article

References (46)

1. Chen L.B., Buchanan J.M. Mitogenic activity of blood components. 1. Thrombin and prothrombin. Proc Natl Acad Sci USA. 72:1975;131-135.
2. Harker L.A., Hanson S.R., Runge M.S. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol. 75:1995;12B-17B.
3. Rosenberg R.D. Actions and interactions of antithrombin and heparin. N Engl J Med. 292:1975;146-151.
4. Clowes A.W., Clowes M.M. Kinetics of cellular proliferation after arterial injury. heparin inhibits rat smooth muscle mitogenesis and migration Circ Res. 8:1986;839-845.
5. Castellot J.J. Jr., Beeler D.L., Rosenberg R.D., Karnovosky M.J. Structural determinants of the capacity to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol. 120:1984;315-320.
6. Roubin G.S., Douglas J.S., King S.B. III, Lin S., Hutchinson N., Thomas G.R., Gruentzig A.R. Influence of balloon size on initial success, acute complications, and restenosis after percutaneous angioplasty in patients with single vessel disease. Circulation. 78:1988;557-565.
7. RITA Trial Participants Coronary angioplasty versus coronary artery bypass surgery. the randomized intervention treatment of angina (RITA) trial Lancet. 341:1993;573-580.
8. Hogg P.J., Jackson C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III. Implications for heparin efficacy Proc Natl Acad Sci USA. 86:1989;619-623.
9. Bar-Shavit R., Eldor A., Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. J Clin Invest. 1096:1989;1989-1996.
10. Okwusidi J., Falcone M., Van Ryn-McKenna J., Hirsh J., Ofosu F.A., Buchanan M.R. In vivo catalysis of thrombin inhibition by antithrombin III and heparin cofactor II and antithrombotic effect. differential effects of dermatan sulphate and unfractionated heparin Thromb Haemorrh Dis. 1(2):1990;77-80.
11. Brister S.J., Buchanan M.R. Heparinless cardiopulmonary bypass (CPB) revisited. a newer strategy to avoid CPB/heparin related bleeding J Cardiothorac Vasc Anesth. 9:1994;317-321.
12. Bendayan P., Boneu B., Boccalon H. Dermatan sulfate is a more potent inhibitor of clot bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost. 71:1994;576-580.
13. Van Ryn-McKenna J., Ofosu F.A., Gray E., Hirsh J., Buchanan M.R. The effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci. 556:1989;304-312.
14. Tollefson D.M., Pestka C.A., Monafo W.J. Activation of heparin cofactor II by dermatan sulphate. J Biol Chem. 258:1983;6713-6716.
15. Jackson R.L., Busch S.J., Cardin A.D. Glycosaminoglycans. molecular properties, protein interactions and role in physiological processes Physiol Rev. 71:1991;481-539.
16. Nagasawa K., Uchiyama H., Wajima Chemical sulfation of preparations of chondroitin 4-and 6-sulfate and dermatan sulfate. Carbohydr Res. 158:1986;183-190.
17. Linhardt R.J., Hileman R.E. Dermatan sulfate as a potential therapeutic agent. Gen Pharmacol. 26:1995;443-451.
18. Fareed J., Hoppensteadt D., Walenga J.M., Ahsan A., Coyne E., Breddin H.S. Molecular and functional heterogeneity in dermatan sulfate preparation. Semin Thromb Haemost. 17:1991;174-180.
19. Maimone M.M., Tollefsom D.M. Structure of dermatan sulfate hexassacharide that binds to heparin cofactor II with high affinity. J Biol Chem. 265:1990;18263-18271.
20. Murata K. Distribution of acidic glycosaminoglycans, lipids and water in normal human cerebral arteries of various ages. Stroke. 16:1985;687-694.
21. Buchanan M.R., Boneu B., Ofosu F.A., Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood. 65:1985;198-201.
22. Imbimbo B.P., Sie P., Agnelli G., Saivin S., Dupony D., Damiami M., Houin G., Gianese F. Intramuscular dermatan sulfate MF701 in patients with hip fracture. relationship between pharmacokinetics and antithrombotic efficiacy Thromb Haemost. 71:1994;553-557.
23. Ryan K.E., Lane D.A., Flynn A., Ireland H., Boisclair M., Sheppard J., Curtis J.R. Antithrombotic properties of dermatan sulfate (MF701) in haemodialysis for chronic renal failure. Thromb Haemost. 68:1992;563-569.
24. Cohen A.T., Phillips M.J., Edmondson R.A., Melissari E., Vaidynathan I., Kakkar V.V. Dermatan sulphate for prophylaxis of deep vein thrombosis (DVT) in elective hip surgery. a dose finding study Thromb Haemost. 69:1993;621.
25. Van Ryn-McKenna J., Ofosu F.A., Hirsh J., Buchanan M.R. The antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulfation. Br J Haematol. 71:1989;265-270.
26. Fernandez F., Van Ryn J., Ofosu F.A., Hirsh J., Buchanan M.R. The hemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol. 64:1986;309-317.
27. Taliani M.R., Agnelli G., Nenci G.G., Gianese F. Dermatan sulphate in patients with heparin-induced thrombocytopenia. Br J Haematol. 104:1999;87-89.
28. Thomas D.P., Merton R.E., Barrowcliffe T.W. Relative efficacy of heparin and related GAGs as antithrombotics. Ann NY Acad Sci. 556:1989;313-322.
29. Van Gorp CL, Buchanan MR, Brister SJ, Linhardt RJ. Dermatan disulfate, an inhibitor of thrombin generation and complement activation. UD Patent 5,922,690,1999.
30. Larsen M.L., Abildgaard U., Teien A.N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-phe-pip-arg-p-NA (S-2238). Thromb Res. 13:1978;285-288.
31. Teien A.N., Lie M., Abildgaard U. Assay of heparin in plasma using a chromogenic substrate of activated Factor Xa. Thromb Res. 8:1976;413-416.
32. Roden L., Baker J.R., Cifonelli J.A., Matthews M.B. Isolation and characterization of connective tissue polysaccharides. Methods Enzymol. 28:1972;73-140.
33. Liberti P.A., Stivala S.S. Physiochemical studies of fractionated bovine heparin. II. Viscosity as a function of ionic strength. Arch Biochem Biophys. 119:1967;510-518.
34. Olfert E.D., Cross B.M., McWilliam A.A. Canadian Council of Animal Care. guide to the Care and Use of Experimental Animals:1984;Bradda Printing Incorp, Ottawa. p. 2.
35. Ghigliotti G., Waissbluth A.R., Speidel C., Abendschein D.R., Eisenberg P.R. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol. 18:1998;250-257.
36. Buchanan M.R., Brister S.J. Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment. relative effects of heparin and dermatan sulphate Thromb Res. 91:1998;157-167.
37. Hogg P.J., Bock P.E. Modulation of thrombin and heparin activities by fibrin. Thromb Haemost. 77:1997;424-433.
38. Buchanan M.R., Maclean G.A., Brister S.J. Evidence for a conformational change of surface-bound thrombin that promotes vessel wall thrombogenicity. selective and sustained inhibition by Intimatan but not by heparin Thromb Haemost. 81(Suppl):1999;1309.
39. MINITAB Reference Manual. Valley Forge, PA; MINITAB Inc., State College, 1988;8.1-36;10.1-15.
40. Schiele F., Lindgaerde F., Eriksson H., Bassand J.B., Wallmark A., Hansson P.O., Crollier G., Sjo M., Moia M., Cameza A., Smyth V., Waller M. Subcutaneous recombinant hirudin (HBW 823) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs. a multicentre prospective dose-finding randomized trial Thromb Haemost. 77:1997;834-838.
41. Brill-Edwards P., Van Ryn-McKenna J., Cai L., Ofosu F.A., Buchanan M.R. Prevention of thrombus growth by antithrombin III-independent and two direct thrombin inhibitors in rabbits. implications on antithrombotic therapy Thromb Haemost. 68:1992;424-427.
42. Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M and the ADVENT Investigators. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for the treatment of proximal deep-vein thrombosis. Thromb Haemost 1997;78:997-1002.
43. Topol E.J., Bonan R., Jewitt D., Sigwart U., Kakkar V.V. Rothman M, de Bono D, Ferguson J, Willerson JT, Stony J, Ganz P, Cohen M, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation. 87:1993;1622-1629.
44. Brister S.J., Ofosu F.A., Buchanan M.R. Thrombin generation during cardiac surgery. is heparin the ideal anticoagulant? Thromb Haemost. 70:1993;259-263.
45. Fontevila C.G., Gill J.B., Brister S.J., Turpie A.G.G., Holder D.A., Ofosu F.A., Buchanan M.R. Contrast media induces thrombin generation during PTCA. Thromb Haemost. 69:1993;1014.
46. Wells J., Nicosia S., Wale C., Smith L.J., Buchanan M.R. Thrombin generation in patients undergoing carotid endartectomy. implications in acute vessel wall closure and antithrombotic therapy Thromb Res. 75:1994;419-426.